Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), racemic ketamine infusion and intranasal esketamine insufflation. The investigators will obtain various indicators, or biomarkers, of a depressed individuals' state before, during, and/or after these treatments. Such biomarkers include neurobehavioral testing, neuroimaging, electroencephalography, cognitive testing, vocal recordings, epi/genetic testing, and autonomic nervous system measures (i.e. "fight-or-flight" response). The results obtained from this study may provide novel antidepressant treatment response biomarkers, with the future goal of targeting a given treatment to an individual patient ("personalized medicine").

Interventions

  • DRUG Ketamine
  • DEVICE Transcranial Magnetic Stimulation (TMS)
  • DEVICE Electroconvulsive Therapy (ECT)
  • DRUG Esketamine
  • DEVICE Deep Transcranial Magnetic Stimulation (dTMS)

Study Locations (1)

Iowa

  • University of Iowa Health Care — Iowa City

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2020-11-02
Est. Completion 2050-08

Sponsor

Mark Niciu

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04480918

The ClinicalTrials.gov registry entry for NCT04480918 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mark Niciu, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 7 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 5 interventions — of which Ketamine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04480918 reports 1 study location spanning 1 distinct geographic area — top geographies include Iowa. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04480918 about?

NCT04480918 is a clinical study titled "University of Iowa Interventional Psychiatry Service Patient Registry". The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), racemic ketamine infusion an...

What is the current status of trial NCT04480918?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2020-11-02. Estimated completion is 2050-08.

What conditions does trial NCT04480918 study?

This clinical trial studies the following conditions: Major Depressive Disorder, Bipolar Disorder, Obsessive-Compulsive Disorder, Treatment Resistant Depression, Bipolar Depression. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04480918?

The interventions under investigation include: Ketamine (DRUG), Transcranial Magnetic Stimulation (TMS) (DEVICE), Electroconvulsive Therapy (ECT) (DEVICE), Esketamine (DRUG), Deep Transcranial Magnetic Stimulation (dTMS) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04480918?

This trial is sponsored by Mark Niciu, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04480918 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial